cemiplimab,fianlimab
regeneron,sanofi
['melanoma', 'fianlimab', 'cemiplimab', 'regeneron']
significant durable response with fianlimab (anti-lag-3) and cemiplimab (anti-pd-1) in advanced melanoma: post adjuvant pd-1 analysis #asco23 
Chief of Research and Immunotherapy  •  ImmunoOncology  •  Phase I  Clinical Trials  •  Melanoma  •  Cutaneous Oncology